
K N Roy Chengappa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11564416/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia. Schizophrenia Research, 2022, 243, 170-177.	2.0	2
2	Group teletherapy for firstâ€episode psychosis: Piloting its integration with coordinated specialty care during the COVIDâ€19 pandemic. Psychology and Psychotherapy: Theory, Research and Practice, 2021, 94, 382-389.	2.5	22
3	ECT for a pregnant patient with bipolar disorder in the COVIDâ€19 Era: A clinical conundrum. Bipolar Disorders, 2021, 23, 524-527.	1.9	3
4	From Office-Based Treatment to Telehealth: Comparing Clinical Outcomes and Patient Participation in a Psychiatric Intensive Outpatient Program with a Large Transdiagnostic Sample. Telemedicine Journal and E-Health, 2021, , .	2.8	3
5	Racial Differences in S100b Levels in Persons with Schizophrenia. Psychiatric Quarterly, 2020, 91, 137-145.	2.1	8
6	Ensuring care for clozapine-treated schizophrenia patients during the COVID-19 pandemic. Schizophrenia Research, 2020, 222, 499-500.	2.0	14
7	Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions. Schizophrenia Research, 2020, 222, 532-533.	2.0	26
8	Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia. Neuropsychopharmacology, 2018, 43, 1334-1342.	5.4	17
9	A cognitive perspective on mood. Bipolar Disorders, 2018, 20, 180-180.	1.9	0
10	Adjunctive Use of a Standardized Extract of Withania somnifera (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia. Journal of Clinical Psychiatry, 2018, 79, .	2.2	44
11	The Potential Utility of Ashwagandha for Improving Cognitive Dysfunction in Persons with Bipolar or Other Neurocognitive Disorders. , 2017, , 345-371.		0
12	All aboard: the Journal's journey to broader contentâ€ment. Bipolar Disorders, 2017, 19, 412-413.	1.9	1
13	Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. Nicotine and Tobacco Research, 2015, 18, ntv085.	2.6	16
14	Subtle changes in thyroid indices during a placebo-controlled study of an extract of Withania somnifera in persons with bipolar disorder. Journal of Ayurveda and Integrative Medicine, 2014, 5, 241.	1.7	21
15	Varenicline for Smoking Cessation in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, 765-772.	2.2	74
16	Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. Addiction, 2013, 108, 1962-1968.	3.3	19
17	Randomized Placebo-Controlled Adjunctive Study of an Extract of <i>Withania somnifera</i> for Cognitive Dysfunction in Bipolar Disorder. Journal of Clinical Psychiatry, 2013, 74, 1076-1083.	2.2	89
18	A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia. Schizophrenia Research, 2012, 142, 145-152.	2.0	69

K N ROY CHENGAPPA

#	Article	IF	CITATIONS
19	Screening for obstructive sleep apnea among individuals with severe mental illness at a primary care clinic. General Hospital Psychiatry, 2012, 34, 660-664.	2.4	35
20	<i>Atypical mood stabilizers</i> : a new role for neuroleptics?. Bipolar Disorders, 2011, 13, 583-586.	1.9	12
21	Hypomania: hype <i>or</i> mania?. Bipolar Disorders, 2010, 12, 758-763.	1.9	25
22	Editorial. Bipolar Disorders, 2010, 12, 757-757.	1.9	0
23	Long term outcomes in persons with bipolar disorder—Developing versus developed countries. Asian Journal of Psychiatry, 2010, 3, 49.	2.0	1
24	Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disorders, 2009, 11, 34-44.	1.9	98
25	Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. Asian Journal of Psychiatry, 2009, 2, 106-111.	2.0	4
26	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. Journal of Clinical Psychopharmacology, 2009, 29, 193-194.	1.4	2
27	Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disorders, 2008, 10, 566-579.	1.9	40
28	Bipolar Disorder and the Metabolic Syndrome. CNS Drugs, 2008, 22, 655-669.	5.9	115
29	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. Journal of Clinical Psychopharmacology, 2008, 28, 247-248.	1.4	12
30	Weight gain and metabolic issues of medicines used for bipolar disorder. Current Psychiatry Reports, 2007, 9, 521-528.	4.5	27
31	Adjunctive Topiramate Therapy in Patients Receiving a Mood Stabilizer for Bipolar I Disorder. Journal of Clinical Psychiatry, 2006, 67, 1698-1706.	2.2	64
32	Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disorders, 2005, 7, 68-76.	1.9	43
33	The prevalence of the metabolic syndrome in patients with schizoaffective disorder – bipolar subtype. Bipolar Disorders, 2004, 6, 314-318.	1.9	115
34	Treatment of bipolar mania with atypical antipsychotics. Expert Review of Neurotherapeutics, 2004, 4, S17-S25.	2.8	21
35	The Off-Label Use of Clozapine in Adolescents with Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 57-63.	1.3	50
36	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser <i>v.</i> mood stabiliser alone. British Journal of Psychiatry, 2004, 184, 337-345.	2.8	288

K N ROY CHENGAPPA

#	Article	IF	CITATIONS
37	Dosage and Administration Issues of Antipsychotic Agents (and Adjunctive Medicines) in the Acute Stabilization of Psychoses. CNS Spectrums, 2004, 9, 6-10.	1.2	112
38	Rates of response, euthymia and remission in two placeboâ€controlled olanzapine trials for bipolar mania. Bipolar Disorders, 2003, 5, 1-5.	1.9	74
39	A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clinical Therapeutics, 2003, 25, 530-541.	2.5	56
40	A Random-Assignment, Double-Blind, Clinical Trial of Once- vs Twice-Daily Administration of Quetiapine Fumarate in Patients with Schizophrenia or Schizoaffective Disorder: A Pilot Study. Canadian Journal of Psychiatry, 2003, 48, 187-194.	1.9	21
41	Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy. Archives of General Psychiatry, 2002, 59, 62.	12.3	410
42	Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open-label, nonrandomized chart review. Clinical Therapeutics, 2002, 24, 1576-1584.	2.5	108
43	The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 437-440.	4.8	16
44	Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. European Psychiatry, 2001, 16, 186-190.	0.2	78
45	Efectos a largo plazo del topiramato sobre la inestabilidad del estado de ánimo bipolar, el cambio de peso y el control glucémico: una serie clÃnica. European Psychiatry (Ed Española), 2001, 8, 361-365.	0.0	0
46	Anticholinergic Differences Among Patients Receiving Standard Clinical Doses of Olanzapine or Clozapine. Journal of Clinical Psychopharmacology, 2000, 20, 311-316.	1.4	68
47	Clozapine Reduces Severe Self-Mutilation and Aggression in Psychotic Patients With Borderline Personality Disorder, Journal of Clinical Psychiatry, 1999, 60, 477-484.	2.2	117